When injury occurs, this balance shifts to strongly elevate NOS2 expression specifically in healing contexts, channeling nitric oxide toward tissue repair
(2015) described the development of angiotensin IV analogs including Dihexa and their HGF/c-Met potentiation mechanism (PMID: 25455861) Expression of Concern: The landmark 2012 paper describing Dihexa's cognitive effects received an expression of concern from the journal (PMID: 34551989), citing data integrity issues including questioned Western blot images Retraction: A follow-up paper from the same research group was retracted (PMID: 40312093), further undermining the evidence base for Dihexa's reported effects No Human Studies: No clinical trials, pharmacokinetic studies, or safety assessments have been conducted in humans Limited Independent Replication: The core claims about Dihexa's cognitive-enhancing effects have not been independently replicated by groups outside the original laboratory The Evidence Gap: This comparison starkly illustrates the difference between a compound with decades of clinical validation (Cerebrolysin) and one with provocative preclinical data undermined by integrity concerns (Dihexa)
For best results, follow guidance from a healthcare provider familiar with peptide therapy and supplementation
Uses, dosage, & side effects
7 Underlying mechanisms include obesity-related comorbidities (T2DM, cardiovascular and renal diseases), immune system impairments facilitating a systemic diffusion of infection, increased type 2 inflammation with effects on the lung parenchyma, raised IL-6 levels, and abnormal secretion of adipokines and cytokines inducing low-grade inflammation
